ASCO 2019 | FIERCE-22 trial: vofatamab with pembrolizumab for urothelial carcinoma

Arlene Siefker-Radtke

Here, Arlene Siefker-Radtke, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, provides an updates of the FIERCE-22 trial (NCT03123055) looking vofatamab with pembrolizumab for urothelial carcinoma. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video